The main goal of the University of Chicago (UChicago) Digestive Diseases Research Core Center (DDRCC) for Interdisciplinary Study of Inflammatory Intestinal Disorders (C-IID) is to foster and facilitate interdisciplinary and innovative, patient-oriented, research in the field of complex inflammatory digestive diseases (DD), to understand and therapeutically exploit discoveries to improve the health of patients with DD. The UChicago C-IID is now in its 29th year, and, despite being a highly focused research program, has a multidisciplinary research base, with 46 full and 25 associate member investigators, and a total annual direct funding for DD that has increased by more than 40% since the last funding cycle, with $21.1 million of direct cost (not including funding from associate members). The ongoing CENTRAL HYPOTHESIS is that advances in care of patients with complex inflammatory diseases of the bowel requires a structure that empowers interdisciplinary clinical and discovery research investigating the mechanisms disrupting intestinal homeostasis and driving inflammation to identify therapeutic targets and foster translation of basic discoveries to development of new preventive and curative treatments. Taking-into-account the evolving scientific and technology advances and trends, and the interests of our members, we have re-aligned members around four C-IID cores that embrace four major interrelated research themes: Microbiome & Metabolism, Genetics, Genomics & Computation, Immune & Tissue response, and Translational & Clinical. Our OVERALL SPECIFIC AIMS are to: (i) build a highly collaborative, multidisciplinary team, (ii) identify and foster young investigators working in DD-related research, (iii) build a fully integrated translational research infrastructure with state-of-the-art core facilities and cutting-edge, high quality, and cost-effective services and resources, (iv) support a robust enrichment program, (v) promote interactions between the C-IID and other UChicago NIDDK centers and existing C-IID (especially with the Midwest DDRCC alliance). The C-IID has received tremendous institutional support as 1 of 5 priority areas designated for development by the Biological Sciences Division. The C-IID has successfully supported new investigators, but also drawn in talented scientists outside of the field of DD (8 now full members since 2015). Over the past two funding cycles, the P&F program has resulted in over $20.1M in extramural funds, or a 20 to 1 return- on-investment. Furthermore, 43% of the 322 publications acknowledging the C-IID for its support were coauthored by two or more C-IID members, indicating a high level of collaborative science. There was a 5-fold increase in the number of co-authored high impact papers (Impact factor>15) compared to the previous funding cycle. Thus, the C-IID has successfully met its goals of advancing the science and translation of discovery in inflammatory DD. The C-IID as a whole is greater than the sum of its parts. It provides strategic vision, cutting-edge, high quality, and cost-effective services and resources, and gives opportunity to current and next generation scientists to flourish in a highly collaborative and productive environment.

Public Health Relevance

The main goal of the University of Chicago (UChicago) Digestive Diseases Research Core Center for Interdisciplinary Study of Inflammatory Intestinal Disorders (C-IID) is to foster and facilitate interdisciplinary and innovative and patient-oriented research in the field of complex inflammatory digestive diseases, to understand and therapeutically exploit discoveries to improve the health of patients with DD. The C-IID has successfully met its goals of advancing the science and translation of discovery in complex diseases of the bowel. The C-IID is greater than the sum of its parts. It provides strategic vision, cutting-edge, high quality, and cost-effective services and resources, and gives opportunity to current and next generation scientists to flourish in a highly collaborative and productive environment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK042086-31
Application #
10049110
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Perrin, Peter J
Project Start
1996-12-01
Project End
2025-11-30
Budget Start
2021-03-18
Budget End
2022-01-31
Support Year
31
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Chen, Edmund B; Cason, Cori; Gilbert, Jack A et al. (2018) Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 22:1112-1123
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Ruderman, Sarah; Eshein, Adam; Valuckaite, Vesta et al. (2018) Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer. BMC Cancer 18:814
Chew, Justin; Leypunskiy, Eugene; Lin, Jenny et al. (2018) High protein copy number is required to suppress stochasticity in the cyanobacterial circadian clock. Nat Commun 9:3004
McIntosh, Christine M; Chen, Luqiu; Shaiber, Alon et al. (2018) Gut microbes contribute to variation in solid organ transplant outcomes in mice. Microbiome 6:96
Dugas, Lara R; Lie, Louise; Plange-Rhule, Jacob et al. (2018) Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. BMC Public Health 18:978
Panés, Julian; Vermeire, Séverine; Lindsay, James O et al. (2018) Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis 12:145-156
Overstreet, A M; LaTorre, D L; Abernathy-Close, L et al. (2018) The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol 11:1454-1465
Delmont, Tom O; Eren, A Murat (2018) Linking pangenomes and metagenomes: the Prochlorococcus metapangenome. PeerJ 6:e4320
Feagan, Brian G; Schwartz, David; Danese, Silvio et al. (2018) Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis 12:621-626

Showing the most recent 10 out of 697 publications